Celgene (NASDAQ:CELG) received a $112.00 price objective from Cantor Fitzgerald in a report issued on Wednesday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 8.22% from the company’s current price.
CELG has been the subject of several other reports. Royal Bank of Canada cut their target price on shares of Celgene from $166.00 to $148.00 and set a “top pick” rating for the company in a research note on Friday, October 27th. Leerink Swann reaffirmed a “buy” rating and set a $156.00 target price on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley cut their target price on shares of Celgene from $120.00 to $115.00 and set an “underweight” rating for the company in a research note on Monday, October 23rd. SunTrust Banks cut their target price on shares of Celgene from $156.00 to $127.00 and set a “buy” rating for the company in a research note on Friday, October 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $131.18.
Shares of Celgene (NASDAQ:CELG) traded down $1.33 during midday trading on Wednesday, hitting $103.49. 1,430,000 shares of the stock were exchanged, compared to its average volume of 6,290,000. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $81,480.00, a PE ratio of 24.41, a PEG ratio of 0.68 and a beta of 1.77. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.58 earnings per share. sell-side analysts expect that Celgene will post 6.69 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the business. Arcadia Investment Management Corp MI lifted its holdings in shares of Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the last quarter. Thompson Davis & CO. Inc. lifted its holdings in shares of Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the last quarter. Robecosam AG bought a new stake in shares of Celgene in the 3rd quarter worth about $114,000. Capital Bank & Trust Co lifted its holdings in shares of Celgene by 166.8% in the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares during the last quarter. Finally, Guidant Wealth Advisors bought a new stake in shares of Celgene in the 3rd quarter worth about $119,000. Institutional investors and hedge funds own 79.85% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Celgene (CELG) Given a $112.00 Price Target at Cantor Fitzgerald” was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.truebluetribune.com/2018/01/17/celgene-celg-given-a-112-00-price-target-at-cantor-fitzgerald-2.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.